Genmab ADR (GMAB): Next-Year EPS Estimate 45.25%
As of 2026-06-04, Genmab ADR (GMAB) has a next-year EPS growth estimate of 45.25%.
On 2026-06-04, analyst consensus for GMAB's next-year EPS growth shifted from 44.92% to 45.25% — a positive change of 0.33 percentage points. Current-year growth is projected at -25.10%.
Current Snapshot
- Sector
- Healthcare
- Industry
- Biotechnology
- EPS growth next year
- 45.25%
- EPS growth this year
- -25.10%
- EPS next quarter (est)
- $0.34
- Last price
- $24.73
EPS Revision History
| Date | EPS Next Y | EPS This Y | Next Q (est) | Price |
|---|---|---|---|---|
| 2026-06-04 | 45.25% | -25.10% | $0.34 | $24.73 |
| 2026-06-03 | 44.92% | -24.34% | $0.34 | $23.88 |
| 2026-06-02 | 44.92% | -24.34% | $0.34 | $23.85 |
| 2026-06-01 | 44.92% | -24.34% | $0.34 | $25.45 |
| 2026-05-31 | 44.22% | -24.05% | $0.34 | $26.33 |
| 2026-05-28 | 44.22% | -24.05% | $0.34 | $27.04 |
| 2026-05-27 | 46.37% | -24.31% | $0.34 | $26.71 |
| 2026-05-26 | 45.83% | -24.15% | $0.34 | $26.89 |
| 2026-05-25 | 46.27% | -24.97% | $0.34 | $26.87 |
| 2026-05-24 | 46.27% | -24.97% | $0.34 | $26.87 |
| 2026-05-21 | 45.73% | -24.54% | $0.34 | $27.05 |
| 2026-05-20 | 45.73% | -24.57% | $0.34 | $27.21 |
| 2026-05-19 | 46.30% | -25.01% | $0.34 | $25.68 |
| 2026-05-18 | 46.30% | -25.01% | $0.34 | $26.37 |
| 2026-05-17 | 46.30% | -25.01% | $0.34 | $26.54 |
| 2026-05-14 | 46.30% | -25.01% | $0.34 | $26.90 |
| 2026-05-13 | 46.55% | -25.14% | $0.34 | $26.52 |
| 2026-05-12 | 46.55% | -25.14% | $0.34 | $27.09 |
| 2026-05-11 | 47.17% | -25.58% | $0.34 | $26.18 |
| 2026-05-10 | 46.98% | -26.03% | $0.34 | $26.43 |
| 2026-05-07 | 45.10% | -24.31% | $0.16 | $27.06 |
| 2026-05-06 | 45.10% | -24.31% | $0.16 | $27.89 |
| 2026-05-05 | 45.10% | -24.31% | $0.16 | $27.52 |
| 2026-05-04 | 45.10% | -24.31% | $0.16 | $27.04 |
| 2026-05-03 | 45.12% | -24.32% | $0.16 | $26.45 |
| 2026-04-30 | 45.12% | -24.32% | $0.16 | $26.52 |
| 2026-04-29 | 45.55% | -24.55% | $0.16 | $26.11 |
| 2026-04-28 | 45.55% | -24.55% | $0.16 | $26.79 |
| 2026-04-27 | 45.53% | -24.54% | $0.16 | $26.64 |
| 2026-04-26 | 45.53% | -24.54% | $0.16 | $26.87 |
Recent News
Screen Performance
Aggregate stats across all 1761 tickers our top-EPS-revision screen has flagged over the past 64 days.
- Median return since detection
- +5.1%
- % of tickers in the green
- 62%
- Median return on winners
- +17.5%
- Large revisions captured
- 746
Past detection performance reflects the price change between when a ticker first entered our screen and the most recent observation. Not a forward-looking forecast.
Frequently Asked Questions
What is Genmab ADR's next-year EPS growth estimate?▾
As of 2026-06-04, Genmab ADR (GMAB) has a next-year EPS growth estimate of 45.25%, based on analyst consensus.
When was the latest EPS estimate revision for GMAB?▾
The most recent revision occurred on 2026-06-04, when analysts adjusted the next-year EPS growth estimate from 44.92% to 45.25%.
What sector and industry does Genmab ADR belong to?▾
Genmab ADR operates in the Healthcare sector, specifically the Biotechnology industry.
How often is this EPS estimate data updated?▾
EPS revision data is refreshed daily from analyst consensus estimates. GMAB appears on this page because it was flagged by our daily top-EPS-revision-performer screen.
EPS revision data sourced from analyst consensus estimates, refreshed daily. Genmab ADR (GMAB) appears here because it was detected by our daily top-EPS-revision-performer screen.
← All reports